Lonafarnib/ritonavir and peg-interferon alfa drive histological improvement and inflammation resolution in chronic HDV
Results of the multicenter phase 3 D-LIVR study
Lonafarnib/ritonavir with or without peginterferon achieves rapid, durable responses in a chronic hepatitis D:
Extended analyses from the phase 3 D-LIVR trial